Renvela: Uses, Dosage & Side Effects
A non-calcium phosphate binder for controlling high blood phosphorus levels in chronic kidney disease and dialysis patients
Renvela (sevelamer carbonate) is a phosphate binder used to control hyperphosphatemia — elevated phosphorus levels in the blood — in patients with chronic kidney disease (CKD). When the kidneys can no longer effectively remove phosphorus from the body, blood levels rise and can lead to serious complications including vascular calcification, bone disease, and cardiovascular events. Renvela works by binding dietary phosphate in the gastrointestinal tract, preventing its absorption. Unlike calcium-based phosphate binders, sevelamer does not contribute additional calcium to the body, making it a preferred choice for patients at risk of hypercalcemia or vascular calcification. Renvela is approved for use in adults on hemodialysis or peritoneal dialysis, as well as in CKD patients not yet on dialysis whose serum phosphorus levels are elevated.
Quick Facts: Renvela
Key Takeaways
- Renvela (sevelamer carbonate) is a non-calcium, non-metal phosphate binder that controls high phosphorus levels in chronic kidney disease patients by binding dietary phosphate in the gut and preventing its absorption into the bloodstream.
- It is approved for adults on hemodialysis or peritoneal dialysis, and for non-dialysis CKD patients with serum phosphorus levels at or above 1.78 mmol/L (5.5 mg/dL), and should be used alongside calcium supplements and vitamin D as part of a comprehensive treatment plan.
- Tablets must be taken with meals, swallowed whole (never crushed, chewed, or broken), with a typical starting dose of 800–1600 mg three times daily, adjusted based on regular serum phosphorus monitoring every 2–4 weeks.
- Unlike calcium-based phosphate binders, sevelamer does not add calcium to the body, which may reduce the risk of vascular calcification — a major contributor to cardiovascular morbidity and mortality in CKD patients.
- Constipation is the most common side effect and may be an early sign of bowel obstruction; patients should also be aware that sevelamer can reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid, and can interact with several important medications including ciprofloxacin, ciclosporin, and levothyroxine.
What Is Renvela and What Is It Used For?
Renvela contains sevelamer carbonate as its active substance. Sevelamer is a synthetic, non-absorbed, cross-linked polymer that acts as a phosphate binder in the gastrointestinal tract. Unlike traditional phosphate binders that contain calcium or aluminum, sevelamer is a calcium-free, metal-free compound. This distinction is clinically significant because many patients with chronic kidney disease already have elevated calcium levels or are at risk of calcium overload from other treatments, and excessive calcium intake has been linked to accelerated vascular calcification.
Under normal circumstances, healthy kidneys efficiently regulate phosphorus levels in the blood by excreting excess phosphorus in the urine. In patients with chronic kidney disease, however, the kidneys progressively lose this ability. As the glomerular filtration rate (GFR) declines, phosphorus excretion decreases, leading to a gradual rise in serum phosphorus levels — a condition known as hyperphosphatemia. This disturbance is a key component of the broader syndrome of CKD-Mineral and Bone Disorder (CKD-MBD), which encompasses abnormalities in calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, along with changes in bone turnover, mineralization, and volume, as well as vascular or other soft tissue calcification.
Elevated serum phosphorus is not merely a laboratory finding; it has profound clinical consequences. Persistent hyperphosphatemia stimulates secondary hyperparathyroidism, wherein the parathyroid glands produce excessive PTH in an attempt to restore phosphorus-calcium balance. Over time, this leads to renal osteodystrophy — a spectrum of bone diseases including osteitis fibrosa cystica (high-turnover bone disease), adynamic bone disease (low-turnover bone disease), and osteomalacia. Patients may experience bone pain, pathological fractures, and skeletal deformities.
Perhaps even more importantly, elevated phosphorus promotes vascular calcification — the deposition of calcium-phosphate crystals within the walls of blood vessels and cardiac valves. Vascular calcification stiffens arteries, increases pulse pressure, contributes to left ventricular hypertrophy, and substantially raises the risk of cardiovascular events. Cardiovascular disease is the leading cause of death in patients with chronic kidney disease, and hyperphosphatemia is recognized as an independent risk factor for mortality in this population. Large observational studies, including the Dialysis Outcomes and Practice Patterns Study (DOPPS), have demonstrated a graded relationship between serum phosphorus levels and mortality risk in hemodialysis patients.
Renvela addresses hyperphosphatemia by working locally in the gastrointestinal tract. When taken with meals, the sevelamer polymer binds to dietary phosphate through ionic exchange and hydrogen bonding. The phosphate-sevelamer complex is not absorbed and is excreted in the feces, effectively reducing the amount of phosphorus that enters the bloodstream from food. This mechanism of action means that Renvela must be taken with every meal to be effective, as it only binds phosphate that is present in the gut at the time of ingestion.
International guidelines from KDIGO (Kidney Disease: Improving Global Outcomes) recommend maintaining serum phosphorus levels toward the normal range in CKD patients. For dialysis patients, this typically means targeting serum phosphorus below 1.78 mmol/L (5.5 mg/dL). Effective phosphate management requires a combination of dietary phosphorus restriction, adequate dialysis, and phosphate binder therapy. Renvela is one of the most widely prescribed phosphate binders worldwide and plays a central role in this multi-pronged approach.
Approved Indications
Renvela is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and regulatory authorities in numerous countries for the following uses:
- Hemodialysis patients: Control of hyperphosphatemia in adult patients receiving hemodialysis, the most common form of renal replacement therapy. Hemodialysis removes some phosphorus from the blood, but it is usually insufficient on its own, and phosphate binders are needed to supplement dietary restriction.
- Peritoneal dialysis patients: Control of hyperphosphatemia in adult patients receiving peritoneal dialysis, an alternative form of dialysis performed at home using the peritoneal membrane as a filter. Peritoneal dialysis may remove somewhat more phosphorus than hemodialysis, but phosphate binders remain necessary for most patients.
- Non-dialysis CKD patients: Control of hyperphosphatemia in adult patients with chronic kidney disease not on dialysis, whose serum phosphorus levels are at or above 1.78 mmol/L (5.5 mg/dL). This indication recognizes that phosphorus management should begin before the initiation of dialysis to prevent the downstream consequences of prolonged hyperphosphatemia.
Renvela should be used as part of a comprehensive treatment approach that may also include dietary phosphorus restriction, calcium supplementation (when appropriate), vitamin D therapy, and adequate dialysis. The goal is to maintain phosphorus, calcium, and PTH levels within the target ranges recommended by international guidelines, thereby reducing the risk of bone disease, vascular calcification, and cardiovascular events.
Additional Metabolic Benefits
Beyond its primary phosphate-binding action, sevelamer has been shown in clinical studies to have additional metabolic effects that may benefit CKD patients. Sevelamer lowers low-density lipoprotein (LDL) cholesterol levels, likely by binding bile acids in the gut in a manner similar to bile acid sequestrants. Several studies have demonstrated reductions in LDL cholesterol of 15–30% with sevelamer therapy. Sevelamer may also modestly increase high-density lipoprotein (HDL) cholesterol and reduce levels of uric acid and C-reactive protein (CRP), a marker of systemic inflammation. While these effects are considered secondary, they may contribute to improved cardiovascular outcomes in a population at very high cardiovascular risk.
What Should You Know Before Taking Renvela?
Contraindications
There are specific situations in which Renvela must not be used. Understanding these absolute contraindications is essential before starting treatment.
- Hypersensitivity: Do not take Renvela if you are allergic to sevelamer carbonate or any of the other ingredients in the product (microcrystalline cellulose, sodium chloride, zinc stearate, hypromellos, or diacetylated monoglycerides).
- Hypophosphatemia: Do not take Renvela if you have low phosphorus levels in the blood. Your doctor will check your phosphorus levels before starting treatment. Using a phosphate binder when phosphorus is already low could cause dangerously low levels, leading to muscle weakness, respiratory failure, and cardiac complications.
- Bowel obstruction: Do not take Renvela if you have a known bowel obstruction (intestinal blockage). Sevelamer is a bulking polymer that could worsen or complicate an existing obstruction, potentially leading to a surgical emergency.
Warnings and Precautions
Before and during treatment with Renvela, discuss the following conditions with your doctor:
- Swallowing difficulties: If you have trouble swallowing tablets, your doctor may prescribe Renvela powder for oral suspension as an alternative formulation. The 800 mg tablets are relatively large and must be swallowed whole.
- Gastrointestinal motility disorders: If you have conditions that slow the movement of food through your digestive tract (such as gastroparesis or chronic constipation), tell your doctor. Sevelamer may worsen these conditions and increase the risk of bowel complications.
- Frequent vomiting: If you vomit frequently, the effectiveness of Renvela may be reduced because the drug needs to remain in contact with food in the gut to bind phosphate effectively.
- Active inflammatory bowel disease: If you have active inflammation in your bowel, such as Crohn’s disease or ulcerative colitis, use Renvela with caution. Cases of sevelamer crystal deposition in the bowel mucosa have been reported.
- History of major gastrointestinal surgery: If you have had significant surgery on your stomach or intestines, discuss this with your doctor as it may affect how Renvela works and increase the risk of gastrointestinal complications.
Cases of bowel obstruction, bowel perforation, and severe inflammatory bowel disease caused by sevelamer crystal deposition have been reported. If you experience severe abdominal pain, severe bloating, severe constipation, bloody stools, fever, chills, nausea, or vomiting, seek immediate medical attention. Your doctor will determine whether treatment should be continued.
Monitoring During Treatment
Because of both your kidney condition and the effects of Renvela, your doctor will need to monitor several blood parameters regularly:
- Calcium levels: Since Renvela does not contain calcium, you may develop low or high calcium levels. Your doctor may prescribe additional calcium supplements to maintain normal calcium balance.
- Vitamin D levels: Chronic kidney disease itself impairs vitamin D metabolism. Your doctor will monitor vitamin D levels and prescribe supplementation if needed, as Renvela does not provide vitamin D.
- Fat-soluble vitamins (A, E, K) and folic acid: Because sevelamer can bind fat-soluble vitamins and folic acid in the gut, reducing their absorption, your doctor may check these levels periodically and prescribe multivitamin supplements if necessary.
- Bicarbonate levels: Some patients develop abnormal bicarbonate levels or metabolic acidosis during treatment. Regular monitoring of blood bicarbonate is recommended.
If you are on peritoneal dialysis, you are at risk of peritonitis (inflammation of the peritoneal membrane), which can occur in association with dialysis. This risk can be reduced by carefully following sterile technique during bag exchanges. Report any new signs of abdominal discomfort, bloating, pain, tenderness, rigidity, constipation, fever, chills, nausea, or vomiting to your doctor immediately.
Pregnancy and Breastfeeding
The safety of Renvela during pregnancy has not been established in clinical studies. Sevelamer carbonate is not absorbed into the bloodstream, which theoretically limits direct fetal exposure. However, sevelamer may reduce the absorption of fat-soluble vitamins (A, D, E, K) and folic acid, which are critical for normal fetal development. Deficiency of these nutrients during pregnancy can lead to birth defects and other complications. If you are pregnant, think you might be pregnant, or are planning to have a baby, discuss the risks and benefits with your doctor before taking Renvela.
It is not known whether sevelamer passes into breast milk. Given that sevelamer is not systemically absorbed, direct transfer into breast milk is considered unlikely. However, the potential reduction in maternal vitamin absorption could indirectly affect the nutritional quality of breast milk. Discuss with your doctor whether you should breastfeed while taking Renvela.
Children
The safety and effectiveness of Renvela have not been established in children under 6 years of age. Renvela is not recommended for use in children younger than 6. For older children, your doctor will determine the appropriate dose based on the child’s body surface area, serum phosphorus levels, and clinical response.
How Does Renvela Interact with Other Drugs?
Because sevelamer acts as a binding agent in the gastrointestinal tract, it has the potential to bind not only dietary phosphate but also other substances present in the gut at the same time. This means that Renvela can reduce the absorption and effectiveness of various medications if they are taken simultaneously. Understanding these interactions is critical to ensuring that your other treatments remain effective.
Major Interactions
The following drug interactions are considered clinically significant and require careful management:
| Drug | Category | Effect | Management |
|---|---|---|---|
| Ciprofloxacin | Antibiotic (fluoroquinolone) | Sevelamer significantly reduces ciprofloxacin absorption, potentially leading to treatment failure | Do not take at the same time. Separate administration or use alternative antibiotic |
| Ciclosporin | Immunosuppressant | Reduced ciclosporin blood levels, risk of transplant rejection | Monitor ciclosporin levels closely; adjust dose as needed |
| Mycophenolate mofetil | Immunosuppressant | Reduced mycophenolate absorption, decreased immunosuppressive effect | Monitor drug levels; consider timing separation |
| Tacrolimus | Immunosuppressant | Reduced tacrolimus blood levels, risk of transplant rejection | Monitor tacrolimus trough levels closely; adjust dose as needed |
| Levothyroxine | Thyroid hormone | Reduced levothyroxine absorption, hypothyroidism may develop or worsen | Monitor TSH levels more frequently; take levothyroxine separately |
Other Notable Interactions
| Drug Class | Examples | Effect | Management |
|---|---|---|---|
| Antiepileptic drugs | Valproate, carbamazepine, phenytoin | Potential reduction in absorption and blood levels | Monitor drug levels; take antiepileptics 1 hour before or 3 hours after Renvela |
| Antiarrhythmic drugs | Amiodarone, flecainide | Potential reduction in absorption, risk of arrhythmia recurrence | Monitor drug levels and cardiac rhythm; separate dosing times |
| Proton pump inhibitors | Omeprazole, pantoprazole, lansoprazole | May reduce the phosphate-binding effectiveness of sevelamer | Monitor serum phosphorus levels more frequently |
As a general rule, when Renvela needs to be taken alongside other medications, your doctor may advise you to take the other medication 1 hour before or 3 hours after taking Renvela. This timing separation allows the other drug to be absorbed before sevelamer is present in the gut in significant amounts. Your doctor may also monitor blood levels of the co-administered medication more frequently to ensure therapeutic effectiveness is maintained.
Kidney transplant recipients who take immunosuppressant medications (ciclosporin, mycophenolate mofetil, or tacrolimus) must have their drug levels monitored carefully when starting, stopping, or adjusting the dose of Renvela. Subtherapeutic immunosuppressant levels can lead to organ rejection, which is a medical emergency.
What Is the Correct Dosage of Renvela?
Renvela dosing is individualized based on each patient’s serum phosphorus levels. The goal is to bring phosphorus into the target range recommended by international nephrology guidelines (typically below 1.78 mmol/L or 5.5 mg/dL for dialysis patients). Because phosphorus levels depend on dietary intake, dialysis adequacy, and residual kidney function, the dose required can vary considerably between patients.
Adults and Elderly
Standard Dosing
The recommended starting dose is one to two 800 mg tablets taken with each meal, three times per day. This provides a total daily starting dose of 2400–4800 mg. Your doctor will choose the starting dose based on your current serum phosphorus level.
| Serum Phosphorus Level | Recommended Starting Dose | Frequency |
|---|---|---|
| 1.78–2.42 mmol/L (5.5–7.5 mg/dL) | 800 mg (1 tablet) | Three times daily with meals |
| > 2.42 mmol/L (> 7.5 mg/dL) | 1600 mg (2 tablets) | Three times daily with meals |
After starting treatment, your doctor will check your serum phosphorus levels every 2–4 weeks and adjust the Renvela dose as needed. The dose can be increased or decreased in increments of 800 mg (one tablet) per meal to achieve target phosphorus levels. Most patients require between 2400 mg and 4800 mg per day, but some patients may need higher doses. There is no fixed maximum dose; however, doses above 14,400 mg per day have not been well studied.
Renvela tablets must be swallowed whole with water. Do not crush, chew, or break the tablets. Taking Renvela correctly is essential for it to work properly. The tablets have a special film coating that ensures controlled release in the gastrointestinal tract. Always take Renvela after a meal or with food — it does not work effectively on an empty stomach because there is no dietary phosphate to bind.
Children (6 Years and Older)
For children aged 6 years and older, the dose is based on body surface area (BSA) and serum phosphorus levels. Your doctor will calculate the appropriate dose. Renvela is not recommended for children under 6 years of age due to insufficient safety and efficacy data in this age group.
Elderly Patients
No dose adjustment is required for elderly patients. The starting dose and titration schedule are the same as for younger adults. However, elderly patients may be more susceptible to gastrointestinal side effects, particularly constipation, and should be monitored closely.
Missed Dose
If you miss a dose of Renvela, skip the missed dose and take your next dose at the usual time with your next meal. Do not take a double dose to make up for a missed one. Since Renvela works by binding phosphate from the food you eat, there is no benefit to taking it between meals or without food. If you frequently miss doses, speak with your doctor or pharmacist about strategies to improve adherence, as consistent use is important for maintaining phosphorus control.
Overdose
If you take more Renvela than prescribed, contact your doctor immediately. Sevelamer carbonate is not absorbed into the bloodstream, which limits the risk of systemic toxicity. However, an overdose could lead to severely low phosphorus levels (hypophosphatemia), which can cause muscle weakness, confusion, respiratory failure, and cardiac arrhythmias. An overdose could also cause significant gastrointestinal symptoms such as severe constipation, bloating, or bowel obstruction. Treatment is supportive and symptomatic.
If You Stop Taking Renvela
Do not stop taking Renvela without consulting your doctor. Stopping Renvela will cause your blood phosphorus levels to rise, potentially leading to the serious complications described earlier, including vascular calcification, bone disease, and increased cardiovascular risk. If you are considering stopping treatment — for example, due to side effects — discuss alternatives with your doctor first. Phosphorus control is a lifelong necessity for most patients with chronic kidney disease.
What Are the Side Effects of Renvela?
Like all medicines, Renvela can cause side effects, although not everyone experiences them. Most side effects are related to the gastrointestinal tract, which is expected given that sevelamer acts locally in the gut. The overall safety profile of sevelamer carbonate is well established from extensive clinical trials and post-marketing surveillance spanning over two decades. Below is a comprehensive overview of reported side effects organized by frequency.
Very Common
May affect more than 1 in 10 people
- Constipation
- Nausea
- Vomiting
- Upper abdominal pain
Common
May affect up to 1 in 10 people
- Diarrhea
- Abdominal pain
- Indigestion (dyspepsia)
- Flatulence (bloating/gas)
Very Rare
May affect up to 1 in 10,000 people
- Allergic reactions (rash, hives, swelling, difficulty breathing)
Not Known
Frequency cannot be estimated from available data
- Bowel obstruction (intestinal blockage)
- Bowel perforation (hole in the intestinal wall)
- Severe inflammatory bowel disease with sevelamer crystal deposition
- Gastrointestinal bleeding (blood in stool)
- Itching (pruritus)
- Skin rash
- Slow intestinal motility
Understanding Constipation as a Warning Sign
Constipation is the most frequently reported side effect of Renvela and deserves special attention. While mild constipation is common and usually manageable, it can also be an early symptom of a more serious condition — bowel obstruction. If you experience new or worsening constipation, especially if accompanied by abdominal distension, pain, or vomiting, contact your doctor promptly. Your doctor may recommend dietary modifications (increased fiber and fluid intake), a stool softener, or a change in your phosphate binder regimen. In some cases, dose reduction or temporary discontinuation of Renvela may be necessary.
When to Seek Immediate Medical Attention
Certain side effects require immediate medical attention. Seek emergency care or contact your doctor immediately if you experience any of the following:
- Severe abdominal pain, bloating, or cramping: May indicate bowel obstruction or bowel perforation.
- Severe constipation with inability to pass gas or stool: Possible signs of complete bowel obstruction.
- Bloody or black stools: May indicate gastrointestinal bleeding or severe inflammatory bowel disease.
- Fever, chills, nausea, and abdominal tenderness: In peritoneal dialysis patients, may indicate peritonitis.
- Rash, hives, facial swelling, or difficulty breathing: Signs of a potentially serious allergic reaction.
Renvela is unlikely to affect your ability to drive or operate machinery. The drug acts locally in the gastrointestinal tract and is not absorbed into the bloodstream, so it does not affect the central nervous system or cause drowsiness.
How Should You Store Renvela?
Proper storage is important to maintain the effectiveness and safety of Renvela throughout its shelf life. Sevelamer carbonate tablets are sensitive to moisture, so correct storage conditions are essential.
- Temperature: No special temperature storage requirements are needed. Store at room temperature.
- Moisture protection: Keep the bottle tightly closed at all times. The tablets are moisture-sensitive and may deteriorate if exposed to humidity.
- Keep out of reach of children: Store the medication where children cannot access it.
- Expiration date: Do not use Renvela after the expiration date (marked “EXP”) on the bottle and carton. The expiration date refers to the last day of that month.
- Disposal: Do not dispose of medicines in household waste or down the drain. Ask your pharmacist about proper disposal methods. These measures help protect the environment.
Renvela is packaged in high-density polyethylene (HDPE) bottles with polypropylene caps and induction seals to maintain product integrity. Available pack sizes include bottles of 30 or 180 tablets.
What Does Renvela Contain?
Active Ingredient
Each film-coated tablet contains 800 mg of sevelamer carbonate. Sevelamer carbonate is a cross-linked polymeric compound that acts as a non-absorbed phosphate binder in the gastrointestinal tract. It is the carbonate salt form of sevelamer; the earlier formulation, sevelamer hydrochloride (marketed as Renagel), used the hydrochloride salt. The carbonate form was developed because it is less likely to contribute to metabolic acidosis, a common problem in CKD patients. Clinical studies have demonstrated that sevelamer carbonate and sevelamer hydrochloride are equivalent in their phosphate-binding efficacy.
Inactive Ingredients (Excipients)
- Microcrystalline cellulose: A common pharmaceutical excipient used as a binder and filler in tablet formulations.
- Sodium chloride: Used as a processing aid. Each tablet contains less than 1 mmol (23 mg) of sodium, making it essentially sodium-free — an important consideration for patients on sodium-restricted diets.
- Zinc stearate: A lubricant used in the tablet manufacturing process to prevent sticking during compression.
Tablet Coating
- Hypromellos (E464): A film-forming agent that creates the protective coating around the tablet. This coating facilitates swallowing and protects the tablet core.
- Diacetylated monoglycerides: A plasticizer used in the coating to improve its flexibility and uniformity.
Physical Description
Renvela 800 mg tablets are white, oval, film-coated tablets with “RV800” engraved on one side. The distinctive engraving helps with identification. The tablets are packaged in HDPE bottles containing either 30 or 180 tablets. A multi-pack containing 180 tablets (6 bottles of 30) is also available. Not all pack sizes may be marketed in every country.
Each Renvela tablet contains less than 1 mmol (23 mg) of sodium, which means it is essentially sodium-free. This is relevant for patients who need to monitor their sodium intake, as is the case for many people with kidney disease or hypertension.
Frequently Asked Questions About Renvela
Both Renvela and Renagel contain the same active polymer, sevelamer, but they use different salt forms. Renagel contains sevelamer hydrochloride, while Renvela contains sevelamer carbonate. The key clinical difference is that the hydrochloride salt in Renagel can contribute to metabolic acidosis (excess acid in the blood), which is already a common problem in CKD patients. The carbonate form in Renvela was specifically developed to avoid this issue and may help buffer metabolic acidosis instead. Both formulations have equivalent phosphate-binding efficacy.
No, Renvela tablets must be swallowed whole. Do not crush, chew, or break the tablets. If you have difficulty swallowing the 800 mg tablets, talk to your doctor about switching to Renvela powder for oral suspension, which is an alternative formulation designed for patients who cannot swallow tablets. The powder is mixed with water before drinking and provides the same phosphate-binding effect.
Renvela works by binding phosphate from the food you eat in your digestive tract. If you take it on an empty stomach or between meals, there is little or no dietary phosphate present for it to bind, making the dose essentially ineffective. Taking Renvela with or immediately after each meal ensures that the sevelamer polymer is present in the gut at the same time as the phosphate from your food, allowing maximum phosphate binding and removal through the stool.
Yes, sevelamer has been shown to lower LDL (“bad”) cholesterol by 15–30% and may modestly increase HDL (“good”) cholesterol. This effect occurs because sevelamer binds bile acids in the gut, similar to how bile acid sequestrant drugs work. While this cholesterol-lowering effect is considered a secondary benefit rather than a primary indication, it may be advantageous for CKD patients who are at very high cardiovascular risk. Your doctor may take this into account when choosing your phosphate binder.
Renvela begins binding phosphate as soon as it reaches the food in your digestive tract, so each dose works immediately during that meal. However, it typically takes 2–4 weeks of consistent use to see a measurable reduction in your blood phosphorus levels, which is why your doctor will check your levels at 2–4 week intervals initially. Achieving and maintaining target phosphorus levels requires consistent dosing with every meal, combined with dietary phosphorus restriction and adequate dialysis.
If you stop taking Renvela, your blood phosphorus levels will likely rise because your kidneys cannot remove sufficient phosphorus on their own. Elevated phosphorus leads to secondary hyperparathyroidism, bone disease, vascular calcification, and increased cardiovascular risk. These consequences develop gradually over weeks to months, so the effects may not be immediately obvious. Never stop Renvela without discussing alternatives with your doctor.
References
- European Medicines Agency (EMA). Renvela — Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu.
- KDIGO (Kidney Disease: Improving Global Outcomes). 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017;7(1):1–59.
- U.S. Food and Drug Administration (FDA). Renvela (sevelamer carbonate) Prescribing Information. Revised 2024.
- Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617.
- Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International. 2007;72(9):1130–1137.
- Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International. 2002;62(1):245–252.
- Di Iorio B, Bellasi A, Russo D; on behalf of the INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487–493.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- Palmer SC, Gardner S, Tonelli M, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691–702.
- Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68(6):386–391.
Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Nephrology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent expert panel following KDIGO, EMA, and FDA guidelines
Evidence Framework
GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology
Editorial Standards
No commercial funding. Independent medical editorial content with full conflict-of-interest disclosure
This article was written by licensed medical professionals and reviewed according to international clinical guidelines. All medical claims are supported by peer-reviewed evidence at Evidence Level 1A. For our complete editorial policy, see Editorial Standards.